Cargando…

Lasmiditan: A New Promising Drug in Migraine

Detalles Bibliográficos
Autores principales:	Prakash, Sanjay, Rana, Kaushik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232496/ https://www.ncbi.nlm.nih.gov/pubmed/34220050 http://dx.doi.org/10.4103/aian.AIAN_30_21

Ejemplares similares

The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020)

Indian Version of ID-Migraine Questionnaire
por: Prakash, Sanjay, et al.
Publicado: (2023)

Efficacy of lasmiditan for the acute treatment of perimenstrual migraine
por: MacGregor, E Anne, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Budget impact of lasmiditan for the acute treatment of migraine in the United States
por: Milev, Sandra, et al.
Publicado: (2021)

Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
por: Rizzoli, Paul B
Publicado: (2014)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience
por: Blumenfeld, Andrew, et al.
Publicado: (2023)

Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
por: Krege, John H., et al.
Publicado: (2022)

Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
por: Knievel, Kerry, et al.
Publicado: (2019)

Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
por: Oswald, Jessica C, et al.
Publicado: (2018)

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study
por: Kuca, Bernice, et al.
Publicado: (2018)

Utility of Stapedial Reflex in Idiopathic Intracranial Hypertension: The Proof is in the Pudding
por: Prakash, Sanjay, et al.
Publicado: (2022)

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy
por: Anderson, Christopher C, et al.
Publicado: (2023)

Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial
por: Takeshima, Takao, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies
por: Szkutnik-Fiedler, Danuta
Publicado: (2020)

Optimal Dosing of Lasmiditan in the Management of Acute Migraine Attack: A Systematic Review and Meta-analysis
por: Basutkar, Roopa Satyanarayan, et al.
Publicado: (2021)

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study
por: Ashina, Messoud, et al.
Publicado: (2021)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
por: Lipton, Richard B., et al.
Publicado: (2020)

Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021)

Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks
por: Tepper, Stewart J., et al.
Publicado: (2020)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis
por: Ahsan, Marya, et al.
Publicado: (2022)

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
por: Krege, John H, et al.
Publicado: (2019)

The Effect and Safety of 5-HT(1F) Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis
por: Gu, Ping, et al.
Publicado: (2021)

Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial
por: Matsumori, Yasuhiko, et al.
Publicado: (2022)

Finding promising cures for migraine: targeting neuropeptides
Publicado: (2021)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Checkpoint inhibitors and myeloma: promises, deadlocks and new directions
por: Bertamini, Luca, et al.
Publicado: (2020)

An old drug as a promising new cure for the hard-to-treat echinococcosis
por: Zhu, Guan, et al.
Publicado: (2020)

Good news for chronic migraine
por: Pascual, J.
Publicado: (2006)

Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study
por: Kitamura, Shigekazu, et al.
Publicado: (2023)

Commentary to ‘Comorbidity in Finnish migraine families’
por: Russell, Michael Bjørn
Publicado: (2006)

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
por: Doty, Erin Gautier, et al.
Publicado: (2019)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
por: Loo, Li Shen, et al.
Publicado: (2019)

Trigger factors of migraine and tension-type headache
por: Sarchielli, P.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_2u06j71b0jha6u440ubnuqarmq